Abstract: Cellular myofibroblastic tumors other than desmoidtype fibromatosis are often diagnostically challenging due to their relative rarity, lack of known genetic abnormalities, and expression of muscle markers which may be confused with sarcomas with myogenic differentiation. In this study we investigate the molecular alterations of a group of cellular myofibroblastic lesions with in the myofibroma and myopericytoma spectrum for better subclassification. Two index cases were studied by pairedend RNA sequencing for potential fusion gene discovery. One chest wall soft tissue tumor in a 3-month-old girl case showed a SRF-C3orf62 fusion, while the other, a forearm lesion in an 8-year-old girl, showed a SRF-RELA fusion. Further screening of 42 cellular examples of myofibroma/myopericytoma by fluorescence in situ hybridization identified additional 8 cases with recurrent SRF gene rearrangements, 6 of them showing identical SRF-RELA fusions. The cohort was composed of 7 females and 3 males, with a wide age range of 3 months to 63 years (mean = 17). All tumors showed a densely packed growth of oval to spindle cells with fibrillary eosinophilic cytoplasm, arranged either in intersecting fascicles or with a distinct nested pattern around a rich vascular network. Despite the dense cellularity and variable mitotic activity none of the lesions displayed nuclear pleomorphism or necrosis. All tumors showed coexpression for SMA and desmin, in most cases with a strong and diffuse pattern of staining, while myogenin was consistently negative. No distant metastases were seen in the few cases with follow-up information. A control group of 34 well-characterized myofibroblastic and perivascular tumors, including 10 typical myofibromas and 3 myopericytomas, were also investigated for SRF gene abnormalities by fluorescence in situ hybridization and were negative. In summary, we report a subset of cellular variants of myofibroma and myopericytoma showing a smooth muscle-like immunophenotype and harboring recurrent SRF-RELA gene fusions, which mimic sarcomas with myogenic differentiation.
M esenchymal tumors of myofibroblastic lineage represent a morphologically diverse group of sometimes locally aggressive soft tissue tumors that encompass a wide spectrum of pathologic entities. Classification of these tumors can be controversial, due to their relatively rare incidence, morphologic features and clinical presentation overlapping with true sarcomatous processes. Especially challenging are lesions with increased cellularity, which based on their immunoexpression of SMA and/or desmin may be misdiagnosed as either leiomyosarcoma or rhabdomyosarcoma. Particularly difficult are cellular myofibroblastic proliferations in children, that is the cellular myofibroma spectrum, which closely resemble pediatric malignancies, such as infantile fibrosarcoma or spindle cell rhabdomyosarcoma. In addition, most of these myofibroblastic lesions lack well-defined genetic abnormalities, hampering their objective classification.
In the present WHO classification, myofibroma(tosis) belongs to the family of pericytic/perivascular tumors, which also includes myopericytoma, glomus tumor, and angioleiomyoma. 1 However, only glomus tumors have been reported to harbor recurring gene fusions involving members of the NOTCH family, while myofibromas and myopericytomas did not, suggesting different pathogenesis. 2 In addition a small subset (15%) of myopericytomas, mainly located in the skin and thyroid, harbored BRAF mutations, including 1 case with multifocal/ infiltrative clinical presentation, 3 while familial examples of infantile myofibromatosis were reported to have PDGFRB gain-of-function mutations. [4] [5] [6] In this study we investigate a group of cellular myofibroblastic tumors, in the spectrum of cellular myofibroma and myopericytoma, in an attempt to further our understanding of their genetic alterations using various methodologies, including whole transcriptome sequencing and fluorescence in situ hybridization (FISH).
MATERIALS AND METHODS

Case Selection
On the basis of the 2 index cases subjected to RNA sequencing and found to have recurrent SRF gene rearrangements, cases with similar morphology were searched from the personal consultation files or the inhouse material of the 2 senior authors (C.R.A., C.D.F.), previously diagnosed as cellular myofibroma, cellular myopericytoma, or cellular myofibroblastic neoplasms, not otherwise specified. Together with the 2 index cases a total of 44 lesions were selected after rereview of hematoxylin and eosin and immunohistochemical slides. The study group displayed increased cellularity, with variable mitotic activity, but lacked overt features of malignancy, such as hyperchromasia, nuclear pleomorphism, and necrosis. The expression of one or more muscle markers by immunohistochemistry (SMA, desmin, caldesmon) was required for diagnosis as indication of myofibroblastic lineage, but no myogenin staining was present in any of the cases selected. A control group of 34 various myofibroblastic/myopericytic lesions, typically included in the differential diagnosis, were also investigated by FISH for SRF gene abnormalities, such as: 10 typical myofibromas (5 adult, 5 infantile variants), 3 myopericytomas, 6 malignant myopericytomas, 5 low-grade myofibroblastic sarcomas, 10 myofibroblastomas, including 7 mammarytype. The study was approved by the Institutional Review Board.
RNA Sequencing
Total RNA was extracted from frozen tissue from 2 index cases using RNeasy Plus Mini (Qiagen), followed by mRNA isolation with oligo(dT) magnetic beads and fragmentation by incubation at 941C in fragmentation buffer (Illumina) for 2.5 minutes. After gel size-selection (350 to 400 bp) and adapter ligation, the library was enriched by Polymerase Chain Reaction (PCR) for 15 cycles and purified. Paired-end RNA sequencing at read lengths of 50 or 51 bp was performed with the HiSeq 2000 (Illumina). All reads were independently aligned with STAR (version 2.3) 7 against the human reference genome (hg19). The reads were then analyzed by FusionSeq for potential gene fusions. 8 Reverse Transcription-Polymerase Chain Reaction 
RESULTS
Pathologic Findings of Cellular Myofibroma/ Myopericytoma With Recurrent SRF Gene Fusions
The cohort was composed of 7 females and 3 males, with a wide age range at diagnosis, of 3 months to 63 years (mean = 17; median = 14), with most aged 18 or under. The anatomic distribution was quite broad, including 3 in the trunk (chest wall, abdominal wall, inguinal area), 2 in the upper and 2 in the lower extremities, 2 in the head and neck, and 1 intra-abdominal, involving the small bowel wall. The tumors size varied from 1.9 to 7 cm (mean of 4 cm) and occurred preferentially within deep soft tissues (skeletal muscle). None of the tumors were encapsulated, 4 were well-circumscribed, while the remaining had a multinodular or focally infiltrative growth within skeletal muscle or adipose tissue (Fig. 1) . Histologically, 2 cytomorphologic and growth patterns were discerned: one being composed of monomorphic spindle cell arranged in intersecting fascicles (Figs. 1, 2), while the other showing rounded to ovoid cells arranged in either a syncytial growth or a nested architecture around a rich capillary network (Fig. 2) . Three cases showed a distinctive biphasic appearance (cases# 1, 5, 9), reminiscent of myofibroma, with a more primitive component of round to ovoid cells, in sharp demarcation from a differentiated myoid component of spindle cells with fibrillary eosinophilic cytoplasm (Fig. 1 ). Three cases (cases# 3, 6, 8) were composed predominantly of round to ovoid cells arranged in a distinctive nested arrangement, more reminiscent of a cellular myopericytoma, although no whorling pattern was discerned. The remaining cases had mostly a spindle cell appearance arranged in long fascicles. The tumor cells showed ovoid to fusiform nuclei with smooth nuclear contours, fine or vesicular chromatin, and minimal cytologic atypia. There was no hyperchromasia or marked nuclear pleomorphism noted. The mitotic activity was typically low (range : 1 Table 1) . None of the cases showed tumor necrosis, but areas of infarction were noted in 4 cases, 3 being associated with dystrophic calcification (Fig. 2) . Follow-up was available in 5 patients, range 24 to 44 months (mean = 36 mo). Only 1 patient developed 2 local recurrences, and he is now with no evidence of disease, after 44 months since original diagnosis.
There were no significant differences clinically or histologically between the SRF-fusion positive cellular myofibroblastic/myopericytic tumors and the ones that lacked SRF gene abnormalities.
SRF-rearranged Cellular Myofibroblastic/ Myopericytic Tumors Display a Smooth Muscle-like Immunophenotype
All tumors showed reactivity for both SMA and desmin (Table 1) . SMA expression was strong and diffuse in all cases tested (Fig. 1) , while desmin was diffuse in 4 cases (Fig. 1) , multifocal in 5 cases, and focally positive in one case. Caldesmon performed in 3 cases, showed diffuse positivity in one and multifocal reactivity in the other 2. CD34 showed focal positivity in 3 cases. Myogenin was negative in all cases. Because of their increased cellularity and diffuse expression of muscle markers, 3 cases were initially misinterpreted as sarcomas with myogenic differentiation, including congenital spindle cell rhabdomyosarcoma, low-grade leiomyosarcoma, and low-grade myofibroblastic sarcoma.
RNA Sequencing Discovery of Novel and Recurrent SRF-RELA Gene Fusions
RNA sequencing was performed in case #1 and 2 with available frozen tissue. Case 1 showed the presence of a SRF-C3orf62 fusion, which resulted from a t(3;6), while case 2 showed an SRF-RELA fusion, resulting from a t(6;11)(p21.1;q13.1) translocation (Fig. 3A) . The latter fusion candidate was detected by FusionSeq algorithm and the chimeric reads were confirmed by RT-PCR, showing a fusion between SRF exon 4 and RELA exon 11 (Fig. 3B) . Further FISH analysis confirmed both SRF and RELA break-apart signals (Fig. 3C) . The fusion resulted in a significant downregulation of SRF mRNA distal to the break-point and an upregulation of the RELA last exon (exon 11) retained in the fusion (Fig. 3D) .
FISH studies confirmed SRF gene rearrangements in 9 of 42 (21%) cases, while RELA gene break-part was identified in 7 of the 9 cases with SRF gene rearrangements (Table 1) . No SRF gene abnormalities were identified in any of the myofibroblastic tumors included in the control group, suggesting a different molecular pathogenesis.
DISCUSSION
We report herein a group of cellular variants of myofibroma and myopericytoma harboring recurrent gene rearrangements in the SRF (serum response factor) gene, which in the majority of these cases resulted in SRF-RELA gene fusions. The clinical presentation included a wide age-range at diagnosis, but occurred mostly in children and young adults within the deep soft tissues and skeletal muscle at various anatomic sites. The tumors displayed some worrisome histologic features, such as increased cellularity, solid or focally infiltrative growth, and in 2 cases had increased mitotic activity of >10 MF/ 10 HPFs and areas of infarction-type necrosis. By immunohistochemistry tumors consistently showed diffuse reactivity for SMA and in most cases for desmin as well, suggestive of a myoid/smooth muscle immunophenotype. Although there were no notable clinicopathologic differences between the SRF-positive and SRF-negative groups of cellular myofibroblastic lesions tested, the tumors with SRF fusions displayed a more consistent smooth musclelike immunophenotype, with often strong and diffuse coexpression of SMA and desmin, raising the possibility of a sarcoma with myogenic differentiation. Indeed, in 3 of the SRF-fusion positive tumors, alternative diagnoses of low-grade leiomyosarcoma, spindle cell rhabdomyosarcoma or low-grade myofibroblastic sarcoma were suggested on the initial biopsies. The presence of SRF gene abnormalities identified only in a subset (22%) of the cellular myofibroblastic/myopericytic tumors tested further reinforces the genetic heterogeneity within the family of pericytic/perivascular tumors, which encompasses not only myofibroma and myopericytoma, but also glomus tumors and angioleiomyoma. Myofibroma and myopericytoma exist on a morphologic continuum, and any separation is to some extent artificial, most cases being defined based on the classic ends of the spectrum. All lesions investigated here were more cellular than "classic" examples of myofibroma or myopericytoma, having more prominent thin-walled vessels than usual myofibroma, hence exaggerating the overlap with myopericytoma. The distinct smooth muscle-like phenotype seen in the present subset of cellular myofibroma/myopericytoma harboring SRF gene fusions suggests a genetically distinct group of tumors associated with a more differentiated immunophenotype toward myoid lineage. Furthermore none of these SRF genetic abnormalities were noted in the control group including classic examples of both myofibroma and myopericytoma. In addition a recent study has demonstrated that in fact >70% of both classic adult and infantile myofibromas are associated with distinct genetic abnormalities, that is PDGFRB mutations, different from . D, The exon expression showed a significant decrease in the SRF mRNA level distal to the breakpoint, while RELA exon 11 mRNA showed significant upregulation after the break, compared with other myofibroblastic cases lacking this fusion.
our cohort of cases. 9 Moreover, our previous studies have shown that recurrent NOTCH gene rearrangements were only identified in glomus tumors, while the other pericytic/perivascular tumors do not. 2 The serum response factor (SRF) gene on 6p21.1 encodes a ubiquitous nuclear protein, which is a member of MADS (MCM1, Agamous, Deficiens, and SRF) box superfamily of transcription factors, which binds to the serum response element in the promoter region of target genes. This conserved transcription factor during evolution is at the confluence of multiple signaling pathways controlling the transcription of immediate-early response genes and muscle-specific genes, including the homeostasis of cardiac, smooth and skeletal muscle tissues. SRF is required for normal cardiac development and maturation; mouse models of tamoxifen inducible cardiac specific SRF knockout led to heart failure with dilated cardiomyopathy, while constitutive overexpression of SRF gene leads to concentric hypertrophic cardiomyopathy. 10 Furthermore, inactivation of SRF in smooth muscle cells during embryonic development leads to a decrease in the number of perivascular progenitor cells as well as defects in the cytoarchitecture, suggesting a crucial role for SRF in vascular smooth muscle cell differentiation. 11 Several lines of evidence suggest a role for SRF in modulating muscle plasticity; including SRFmutant mice developing growth retardation and a major decrease in muscle mass, the latter resulting from downregulation of skeletal actin and other contractile genes. SRF-related gene fusions have been previously reported in 1 case of congenital/spindle cell rhabdomyosarcoma, showing an SRF-NCOA2 fusion. 12 RELA proto-oncogene, aka, nuclear factor-kappa-B (NF-kB) subunit, encodes a ubiquitous transcription factor involved in several biological processes. Upon activation through inhibitor degradation, RELA translocates from the cytoplasm to the nucleus and activates transcription of specific genes. Similar to SRF, RELA has also been implicated in oncogenic transformation through recurrent chromosomal translocations, with two thirds of supratentorial ependymomas containing oncogenic fusions between RELA and an uncharacterized gene, C11orf95. Similar to RELA fusion-positive ependymomas, our index case (case 2) with SRF-RELA fusion also showed upregulation of the exon 11 RELA mRNA distal to the breakpoint, containing the transactivation domain (Fig. 3) . In ependymomas, the RELA fusion protein accumulates preferentially in the nucleus of ependymoma cells compared with the wild-type RELA protein, which is sequestered in the cytoplasm of unstimulated controls, 13 indicating pathologic activation of the NF-kB pathway. 14 With the advent of next-generation sequencing, an increasing number of novel gene fusions have emerged recently in the spectrum of atypical/malignant myofibroblastic tumors. In 1 such study, Haller et al 15 described 4 patients (2 children and 2 adults) with soft tissue tumors harboring NTRK1-related fusions, displaying a variety of morphologies and immunophenotype, including infantile HPC, myofibroblastic sarcoma and myopericytoma-like. Their cases showed consistently high mitotic activity, ranging from 12 to 17 MF/10 HPFs. It remains unclear if these NTRK1-rearraranged atypical/ malignant myofibroblastic/myopericytic tumors have any relationship to our cohorts, since all 20 cases of myofibromas/myopericytomas, spanning classic, cellular and malignant examples, from our files lacked NTRK1 genetic abnormalities. 16 We believe that the cases described recently by Linos et al, 17 as "myofibroma with atypical features," based on increased cellularity, infiltrative borders and increased mitotic activity (but not increased pleomorphism), resemble closely our cohort and may represent SRF-positive cellular variants of myofibroma or myoepricytoma as described here.
The differential diagnoses of cellular myofibroblastic/myopericytic tumors typically encompass lowgrade sarcomas with variable myogenic differentiation by immunohistochemistry. Low-grade leiomyosarcoma might be difficult to distinguish from our cohort due to the smooth muscle-like immunophenotype; however, none of the SRF-positive cellular myofibroblastic/ myopericytic tumors showed the typical elongated cigarshaped nuclei with nuclear hyperchromasia and overt pleomorphism. Although some of the SRF-positive tumors had a distinct fascicular growth pattern and diffuse desmin reactivity reminiscent of spindle cell rhabdomyosarcoma, none of the cases showed myogenin positivity expected with a skeletal muscle lineage. Another lesion often considered in the differential diagnosis is a lowgrade myofibroblastic sarcoma, which may show significant overlap in both cytomorphology and immunoprofile, but which displays cytologic atypia at least focally, which was completely lacking in our study group.
In conclusion, we describe recurrent SRF gene abnormalities, resulting in novel SRF-RELA gene fusions in a subset of cellular myofibroblastic tumors in the spectrum of cellular myofibroma/myopericytoma. In fact none of the SRF-positive lesions fit the criteria for typical myofibroma or myopericytoma, all displaying atypical and worrisome features, such as: diffuse hypercellularity, increased mitotic figures and in some cases a distinct immunoprofile, with often diffuse and strong coexpression of desmin and SMA, reminiscent of a smooth muscle phenotype. This constellation of findings may represent a potential diagnostic pitfall in children and young adults, causing possible confusion with sarcomas with myogenic differentiation. The follow-up available to date in these patients suggests a benign clinical course, with rare local recurrences if incompletely excised and lack of metastatic potential. The RNA sequencing from one of the index cases indicated that the SRF-RELA fusion triggers opposite effects on the fusion gene partners, with downregulation of SRF mRNA distal to the fusion, while the RELA last exon retained in the fusion showed marked overexpression. Thus further functional studies are required to determine if the pathogenesis of these cellular myofibroblastic/myopericytic tumors is induced by the truncated expression of the muscle specific SRF transcription factor, or driven through RELA upregulation and subsequent NF-kB
